Study of GLS-010 Injection in the Treatment of Classical Hodgkin's Lymphoma
Patients with refractory cHL. Patients will be treated with GLS-010
Classical Hodgkin's Lymphoma
DRUG: GLS-010
Objective response rate, Based on an independent image assessment board, 2 months
PFS, meaningful benefit in PFS based on Lugano 2014, 8 weeks|OS, Overall survival, within 3 years of last patient enrolled|DCR, meaningful benefit in DCR based on Lugano 2014, 8 weeks|DOR, meaningful benefit in DOR based on Lugano 2014, 8 weeks|TTR, meaningful benefit in TTR based on Lugano 2014, 8 weeks
Open, uncontrolled, multi-center, phase II study.